survivin Cancer Research Results

survivin, BIRC5: Click to Expand ⟱
Source:
Type: antiapoptosis protein
Survivin, BIRC5 (Baculoviral IAP Repeat Containing 5) is a potent anti-apoptosis protein that is differentially expressed in cancer and therefore constitutes an important anti-cancer target [49]. Moreover, high expression of survivin plays important role in resistance to chemo- and radiotherapy and has been shown to be related to unfavorable outcome for medulloblastomas.
"Survivin" is a protein that plays a crucial role in regulating cell division and inhibiting apoptosis (programmed cell death). It is part of the inhibitor of apoptosis (IAP) family and is often overexpressed in various types of cancer.
Scientific Papers found: Click to Expand⟱
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,
22- EGCG,    Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics
- in-vitro, PC, CD133+ - in-vitro, PC, CD44+ - in-vitro, PC, CD24+ - in-vitro, PC, ESA+
HH↓, Smo↓, PTCH1↓, PTCH2↓, Gli1↓, GLI2↓, Gli↓, Bcl-2↓, XIAP↓, Shh↓, survivin↓, Casp3↑, Casp7↑, CSCs↓, Nanog↓, cMyc↓, OCT4↓, EMT↓, Snail↓, Slug↓, Zeb1↓, TumCMig↓, TumCI↓, eff↑,
685- EGCG,  CUR,  SFN,  RES,  GEN  The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein
- Analysis, NA, NA
Bcl-2↓, survivin↓, XIAP↓, EMT↓, Apoptosis↑, Nanog↓, cMyc↓, OCT4↓, Snail↓, Slug↓, Zeb1↓, TCF↓,
4682- EGCG,    Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate
- Review, Var, NA
CSCs↓, EMT↓, ChemoSen↑, CD133↓, CD44↓, ALDH1A1↓, Nanog↓, OCT4↓, TumCP↓, Apoptosis↑, p‑GSK‐3β↓, GSK‐3β↑, β-catenin/ZEB1↓, cMyc↓, XIAP↓, Bcl-2↓, survivin↓, Vim↓, Slug↓, Snail↓,
3236- EGCG,  Buty,    Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate
- in-vitro, Colon, RKO - in-vitro, Colon, HCT116 - in-vitro, Colon, HT29
Apoptosis↑, TumCCA?, HDAC1↓, DNMT1↓, survivin↓, HDAC↓, P21↑, NF-kB↑, γH2AX↑, ac‑H3↑, DNAdam↑,
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, DNMTs↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,
5225- EMD,    Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3
- vitro+vivo, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
STAT3↓, Akt↓, cSrc↓, JAK1↓, JAK2↓, SHP1↑, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, Mcl-1↓, survivin↓, VEGF↓, TumCP↓, Casp3↑, cl‑PARP↑, ChemoSen↑, XIAP↓,
1155- F,    The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations
- Review, NA, NA
*toxicity↓, Casp3↑, Casp7↑, Casp8↑, Casp9↑, VEGF↓, angioG↓, PI3K↓, Akt↓, PARP↑, Bak↑, BID↑, Fas↑, Mcl-1↓, survivin↓, XIAP↓, ERK↓, EMT↓, EM↑, IM↓, Snail↓, Slug↓, Twist↓,
2827- FIS,    The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1/CCND1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2↓, IAP2↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,
2829- FIS,    Fisetin: An anticancer perspective
- Review, Var, NA
TumCP↓, TumCI↓, TumCCA↑, TumCG↓, Apoptosis↑, cl‑PARP↑, PKCδ↓, ROS↓, ERK↓, NF-kB↓, survivin↓, ROS↑, PI3K↓, Akt↓, mTOR↓, MAPK↓, p38↓, HER2/EBBR2↓, EMT↓, PTEN↑, HO-1↑, NRF2↑, MMP2↓, MMP9↓, MMP↓, Casp8↑, Casp9↑, TRAILR↑, Cyt‑c↑, XIAP↓, P53↑, CDK2↓, CDK4↓, CDC25↓, CDC2↓, VEGF↓, DNAdam↑, TET1↓, CHOP↑, CD44↓, CD133↓, uPA↓, CSCs↓,
2830- FIS,    Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
- Review, Var, NA
TumCG↓, angioG↓, *ROS↓, TumCMig↓, VEGF↓, MAPK↑, NF-kB↓, PI3K↓, Akt↓, mTOR↓, NRF2↑, HO-1↑, ROS↓, Inflam↓, ER Stress↑, ROS↑, TumCP↓, ChemoSen↑, PTEN↑, P53↑, Casp3↑, Casp8↑, Casp9↑, COX2↓, Wnt↓, EGFR↓, Mcl-1↓, survivin↓, IAP1↓, IAP2↓, PGE2↓, β-catenin/ZEB1↓, DR5↑, MMP2↓, MMP9↓, FAK↓, uPA↓, EMT↓, ERK↓, JNK↑, p38↑, PKCδ↓, BioAv↓, BioAv↑, BioAv↑,
2842- FIS,    Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells
- in-vitro, GC, AGS
TumCCA↑, CDK2↓, P53↑, selectivity↑, MMP↓, DNAdam↑, cl‑PARP↑, mt-ROS↑, eff↓, survivin↓,
5152- GamB,    Gambogic Acid as a Candidate for Cancer Therapy: A Review
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumCI↓, TumMeta↓, angioG↓, eff↑, NF-kB↓, P53↑, P21↑, MDM2↓, HSP90↓, Bcl-2↓, Cyt‑c↑, Casp↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑, Bax:Bcl2↑, ROS↑, SIRT1↓, TrxR1↓, Fas↓, FasL↑, FADD↑, APAF1↑, DNAdam↑, NF-kB↓, STAT3↓, MAPK↓, cFos↓, EGFR↓, Akt↓, mTOR↓, AMPK↑, TumCCA↑, ChemoSen↑, P-gp↓, survivin↓,
5148- GamB,    Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics
- Review, Var, NA
AntiCan↑, angioG↓, ChemoSen↑, RadioS↑, VEGF↓, MMP2↓, MMP9↓, Telomerase↓, TrxR↓, ERK↓, HSP90↓, ROS↑, SIRT1↑, survivin↓, cFLIP↓, Casp3↑, Casp8↑, Casp9↑, BAD↓, BID↓, Bcl-2↓, BAX↑, STAT3↓, hTERT/TERT↓, NF-kB↓, Myc↓, Hif1a↓, FOXD3↑, BioAv↓, BioAv↑, P53↑, eff↓, OCR↓, MMP↓, PI3K↓, Akt↓, BBB↑, TumCG↓, TumMeta↓, BioAv↑,
1972- GamB,  doxoR,    Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression
- in-vitro, BC, NA
eff↑, P-gp↓, ROS↑, survivin↓, p38↑,
801- GAR,  Cisplatin,    Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers
- in-vivo, HNSCC, NA
Apoptosis↑, cycD1/CCND1↓, Bcl-2↓, survivin↓, VEGF↓, TumCG↓, Ki-67↓, CD31↓,
823- GAR,    Garcinol Potentiates TRAIL-Induced Apoptosis through Modulation of Death Receptors and Antiapoptotic Proteins
- in-vitro, BC, MCF-7 - in-vitro, Nor, MCF10 - in-vitro, CRC, HCT116
Casp3↑, Casp9↑, Casp8↑, DR5↑, survivin↓, Bcl-2↓, XIAP↓, cFLIP↓, BAX↑, Cyt‑c↑, ROS↑, GSH↓, *eff↓,
826- GAR,    Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo
- vitro+vivo, HCC, HepG2 - vitro+vivo, Liver, HUH7
STAT3↓, TumCP↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, Mcl-1↓, survivin↓, VEGF↓, TumCCA↑, TumVol↓,
2073- HNK,    Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo
- in-vitro, OS, U2OS - in-vivo, NA, NA
TumCD↑, TumAuto↑, Apoptosis↑, TumCCA↑, GRP78/BiP↑, ROS↑, eff↓, p‑ERK↑, selectivity↑, Ca+2↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑, Bcl-2↓, Bcl-xL↓, survivin↓, LC3B-II↑, ATG5↑, TumVol↓, TumW↓, ER Stress↑,
4522- HNK,  MAG,    Honokiol Is More Potent than Magnolol in Reducing Head and Neck Cancer Cell Growth
- in-vitro, HNSCC, FaDu
AntiCan↑, tumCV↓, eff↑, survivin↓, RadioS↑,
4659- HNK,    Honokiol Eliminates Human Oral Cancer Stem-Like Cells Accompanied with Suppression of Wnt/β-Catenin Signaling and Apoptosis Induction
- in-vitro, Oral, NA
cl‑Casp3↑, survivin↓, Bcl-2↓, CD44↓, Wnt↓, β-catenin/ZEB1↑, EMT↓, Slug↓, Snail↓, CSCs↓, Apoptosis↑,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
4640- HT,    The anti-cancer potential of hydroxytyrosol
- Review, Var, NA
selectivity↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-2↓, BAX↑, MPT↑, Fas↑, PI3K↓, Akt↓, mTOR↓, Mcl-1↓, survivin↓, STAT3↓, EMT↓, TumCI↓, angioG↓, E-cadherin↑, N-cadherin↓, Snail↓, Twist↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, VEGFR2↓, Hif1a↓, CSCs↓, CD44↓, Wnt↓, β-catenin/ZEB1↓,
2924- LT,    Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1
- in-vitro, GC, NA - in-vivo, NA, NA
p‑STAT3↓, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, HSP90↓,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
4779- Lyco,    Lycopene Inhibits Reactive Oxygen Species-Mediated NF-κB Signaling and Induces Apoptosis in Pancreatic Cancer Cells
- in-vitro, PC, PANC1
ROS↓, NF-kB↓, tumCV↓, Casp3↑, Apoptosis↑, OCR↓, MMP↓, CIP2A↓, survivin↓, Casp3↑, Bax:Bcl2↑,
4782- Lyco,    New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, TumCI↓, TumCA↓, ROS↓, MMP2↓, MMP7↓, MMP9↓, VEGF↓, E-cadherin↑, TIMP1↑, TIMP2↑, BioAv↝, *IL12↓, *TNF-α↓, *IL1↓, *IL1β↓, *IL6↓, COX2↓, iNOS↓, *radioP↑, NF-kB↓, survivin↓, Casp3↑, Bax:Bcl2↑,
3486- MF,    Pulsed electromagnetic field potentiates etoposide-induced MCF-7 cell death
- in-vitro, NA, NA
ChemoSen↑, tumCV↓, cl‑PARP↑, Casp7↑, Casp9↑, survivin↓, BAX↑, DNAdam↑, ROS↑, eff↓,
4353- MF,  Chemo,    Pulsed Electromagnetic Field Enhances Doxorubicin-induced Reduction in the Viability of MCF-7 Breast Cancer Cells
- in-vitro, BC, MCF-7
TumCCA↑, Apoptosis↑, eff↑, TumCCA↑, Casp↝, p‑CDK2↓, cycE/CCNE↓, Fas↑, BAX↑, survivin↓, Mcl-1↓, cl‑PARP↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑,
930- MushShi,    Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation
- in-vitro, Ovarian, NA
p‑STAT3↓, PTPN6↑, cycD1/CCND1↓, Bcl-2↓, Mcl-1↓, survivin↓, VEGF↓,
1797- NarG,    Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway
- in-vitro, BC, MDA-MB-231
TumCG↓, β-catenin/ZEB1↓, AntiTum↑, Apoptosis↑, TumCCA↑, P21↑, survivin↓,
1807- NarG,    A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies
- Review, NA, NA
AntiTum↑, TumCP↓, tumCV↓, TumCCA↑, Mcl-1↓, RAS↓, e-Raf↓, VEGF↓, AntiAg↑, MMP2↓, MMP9↓, TIMP2↑, TIMP1↑, p38↓, Wnt↓, β-catenin/ZEB1↑, Casp↑, P53↑, BAX↑, COX2↓, GLO-I↓, CYP1A1↑, lipid-P↓, p‑Akt↓, p‑mTOR↓, VCAM-1↓, P-gp↓, survivin↓, Bcl-2↓, ROS↑, ROS↑, MAPK↑, STAT3↓, chemoP↑,
4630- OLE,    Targeting resistant breast cancer stem cells in a three-dimensional culture model with oleuropein encapsulated in methacrylated alginate microparticles
- in-vitro, BC, NA
Bcl-2↓, BAX↑, Casp3↑, Casp9↑, Vim↓, Slug↓, E-cadherin↑, CSCs↓, P21↑, survivin↝, OCT4↑, Nanog↑, SOX4↑,
2028- PB,    Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms
- Review, Var, NA
HDAC↓, TumCCA↑, P21↑, Dose↝, Telomerase↓, IGFBP3↑, p‑p38↑, JNK↑, ERK↑, BAX↑, Casp3↑, Bcl-2↓, Cyt‑c↝, FAK↓, survivin↓, VEGF↓, angioG↓, DNArepair↓, TumMeta↓, HSP27↑, ASK1↑, ROS↑, eff↑, ER Stress↓, GRP78/BiP↓, CHOP↑, AR↓, other?,
4935- PEITC,    Phenethyl Isothiocyanate Suppresses Inhibitor of Apoptosis Family Protein Expression in Prostate Cancer Cells in Culture and In Vivo
- in-vivo, Pca, LNCaP - in-vivo, Pca, PC3
Apoptosis↑, XIAP↓, survivin↓, *BioAv↑, tumCV↓, eff↓,
4922- PEITC,    Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms
- Review, Var, NA
Risk↓, AntiCan↑, TumCP↓, TumMeta↓, ChemoSen↑, *BioAv↑, *other↝, *Dose↝, Dose↓, *BioAv↑, *Dose↝, *Half-Life↝, *toxicity↝, GSH↓, ROS↑, CYP1A1↑, CYP1A2↑, P450↓, CYP2E1↑, CYP3A4↓, CYP2A3/CYP2A6↓, *ROS↓, *GPx1↑, *SOD1↑, *SOD2↑, Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, Telomerase↓, selectivity↑, MMP↓, Cyt‑c↑, Apoptosis↑, DR4↑, Fas↑, XIAP↓, survivin↓, TumAuto↑, Hif1a↓, angioG↓, MMPs↓, ERK↓, NF-kB↓, EMT↓, TumCI↓, TumCMig↓, Glycolysis↓, ATP↓, selectivity↑, *antiOx↑, Dose↝, other↝, OCR↓, GSH↓, ITGB1↓, ITGB6↓, ChemoSen↑,
3597- PI,    Chronic diseases, inflammation, and spices: how are they linked?
- Review, AD, NA - Review, Park, NA - Review, Var, NA
*NF-kB↓, *MAPK↓, *AP-1↓, *COX2↓, *NOS2↓, *IL1β↓, *TNF-α↓, *PGE2↓, *STAT3↓, *IL10↑, *IL4↓, *IL5↓, P53↑, MMP9↓, MMP2↓, cMyc↓, VEGF↓, STAT3↓, survivin↓, p65↓,
2940- PL,    Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors
- in-vitro, PC, PANC1 - in-vitro, Lung, A549 - in-vitro, Kidney, 786-O - in-vitro, BC, SkBr3
ROS↑, TumCP↓, Apoptosis↑, eff↓, Sp1/3/4↓, cycD1/CCND1↓, survivin↓, cMyc↓, EGFR↓, cMET↓,
2945- PL,    Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells
- in-vitro, CRC, HCT116
ROS↑, SMAD4↑, ChemoSen↑, P53↑, P21↑, BAX↑, Bcl-2↓, survivin↓, TumCMig↓,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
3354- QC,    Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine
- Review, Var, NA
*ROS↓, *IronCh↓, *lipid-P↓, *GSH↑, *NRF2↑, TumCCA↑, ER Stress↑, P53↑, CDK2↓, cycA1/CCNA1↓, CycB/CCNB1↓, cycE/CCNE↓, cycD1/CCND1↓, PCNA↓, P21↑, p27↑, PI3K↓, Akt↓, mTOR↓, STAT3↓, cFLIP↓, cMyc↓, survivin↓, DR5↓, *Inflam↓, *IL6↓, *IL8↓, COX2↓, 5LO↓, *cardioP↑, *FASN↓, *AntiAg↑, *MDA↓,
60- QC,  EGCG,  isoFl,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, pCSCs
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, CSCs↓, Apoptosis↑, TumCMig↓, TumCI↓, CD44↓, CD133↓,
45- QC,    Quercetin Inhibit Human SW480 Colon Cancer Growth in Association with Inhibition of Cyclin D1 and Survivin Expression through Wnt/β-Catenin Signaling Pathway
- in-vitro, Colon, CX-1 - in-vitro, Colon, SW480 - in-vitro, Colon, HT-29 - in-vitro, Colon, HCT116
cycD1/CCND1↓, survivin↓, Wnt/(β-catenin)↓, tumCV↓, TumCCA↑, Apoptosis↑,
47- QC,    Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells
- in-vitro, NSCLC, H460 - in-vitro, NSCLC, A549
TRAIL↑, DR5↑, survivin↓,
77- QC,  EGCG,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, CD44+ - in-vitro, NA, CD133+ - in-vitro, NA, PC3 - in-vitro, NA, LNCaP
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Vim↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, TCF↓, eff↑, CSCs↓, TumCG↓, tumCV↓,
923- QC,    Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health
- Review, Var, NA
ROS↑, GSH↓, Ca+2↝, MMP↓, Casp3↑, Casp8↑, Casp9↑, other↓, *ROS↓, *NRF2↑, HO-1↑, TumCCA↑, Inflam↓, STAT3↓, DR5↑, P450↓, MMPs↓, IFN-γ↓, IL6↓, COX2↓, IL8↓, iNOS↓, TNF-α↓, cl‑PARP↑, Apoptosis↑, P53↑, Sp1/3/4↓, survivin↓, TRAILR↑, Casp10↑, DFF45↑, TNFR 1↑, Fas↑, NF-kB↓, IKKα↓, cycD1/CCND1↓, Bcl-2↓, BAX↑, PI3K↓, Akt↓, E-cadherin↓, Vim↓, β-catenin/ZEB1↓, cMyc↓, EMT↓, MMP2↓, NOTCH1↓, MMP7↓, angioG↓, TSP-1↑, CSCs↓, XIAP↓, Snail↓, Slug↓, LEF1↓, P-gp↓, EGFR↓, GSK‐3β↓, mTOR↓, RAGE↓, HSP27↓, VEGF↓, TGF-β↓, COL1↓, COL3A1↓,
1506- RES,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
DNMTs↓, BRCA1↑, HDAC↓, SIRT1↑, p300↓, survivin↓, HDAC1↓, HDAC3↓, HDAC8↓,
4657- RES,    Resveratrol, cancer and cancer stem cells: A review on past to future
- Review, Var, NA
CSCs↓, CD133↓, Shh↓, Twist↓, Snail↓, MMP2↓, MMP9↓, Smad1↓, CD44↓, ALDH1A1↓, OCT4↓, Nanog↓, STAT3↓, survivin↓, cycD1/CCND1↓, COX2↓, cMyc↓,

Showing Research Papers: 51 to 100 of 143
Prev Page 2 of 3 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 143

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   CYP1A1↑, 2,   CYP2E1↑, 1,   GSH↓, 6,   GSTs↑, 1,   HO-1↓, 3,   HO-1↑, 5,   HO-2↓, 1,   lipid-P↓, 1,   MAD↓, 1,   MDA↑, 1,   NQO1↑, 1,   NRF2↓, 1,   NRF2↑, 7,   Prx4↑, 1,   ROS↓, 4,   ROS↑, 21,   mt-ROS↑, 2,   SIRT3↑, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,   TrxR↓, 3,   TrxR1↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 1,   CDC2↓, 3,   CDC25↓, 2,   MMP↓, 13,   MPT↑, 1,   OCR↓, 4,   e-Raf↓, 1,   c-Raf↓, 1,   XIAP↓, 15,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 3,   ATG7↑, 1,   cMyc↓, 12,   p‑cMyc↑, 1,   CYP3A4↓, 1,   ECAR↝, 1,   GLO-I↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 4,   HK2↓, 2,   lactateProd↓, 1,   LDH↓, 1,   PCK1↓, 1,   PDH↝, 1,   PDK1?, 2,   cl‑PPARα↓, 1,   SIRT1↓, 3,   SIRT1↑, 2,  

Cell Death ⓘ

Akt↓, 13,   Akt↑, 1,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis↑, 18,   ASK1↑, 1,   BAD↓, 1,   Bak↑, 1,   BAX↑, 14,   BAX⇅, 1,   Bax:Bcl2↑, 4,   Bcl-2↓, 23,   Bcl-xL↓, 5,   BID↓, 1,   BID↑, 1,   BIM↑, 1,   Casp↑, 3,   Casp↝, 1,   Casp10↑, 1,   Casp3↑, 23,   cl‑Casp3↑, 2,   Casp7↑, 7,   cl‑Casp7↑, 1,   Casp8↑, 8,   cl‑Casp8↑, 2,   Casp9↑, 15,   cl‑Casp9↑, 2,   cFLIP↓, 3,   Chk2↑, 1,   Cyt‑c↑, 10,   Cyt‑c↝, 1,   Diablo↑, 3,   DR4↑, 2,   DR5↓, 1,   DR5↑, 8,   FADD↑, 1,   Fas↓, 1,   Fas↑, 6,   FasL↑, 1,   hTERT/TERT↓, 2,   IAP1↓, 1,   IAP2↓, 2,   iNOS↓, 4,   JNK↓, 1,   JNK↑, 4,   MAPK↓, 5,   MAPK↑, 2,   Mcl-1↓, 11,   Mcl-1↑, 1,   MDM2↓, 4,   MDM2↑, 1,   Myc↓, 2,   NICD↓, 1,   NOXA↑, 1,   p27↑, 2,   p38↓, 2,   p38↑, 2,   p‑p38↓, 1,   p‑p38↑, 1,   PUMA↑, 1,   survivin↓, 49,   survivin↝, 1,   Telomerase↓, 6,   TNFR 1↑, 1,   TRAIL↑, 1,   TRAILR↑, 2,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

cSrc↓, 1,   EF-1α↓, 1,   FOXD3↑, 1,   HER2/EBBR2↓, 2,   p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 5,  

Transcription & Epigenetics ⓘ

cJun↑, 1,   H3↑, 1,   p‑H3↓, 1,   ac‑H3↑, 1,   H4↑, 1,   HATs↓, 1,   HATs↑, 1,   other?, 1,   other↓, 1,   other↝, 1,   pRB↑, 1,   tumCV↓, 9,  

Protein Folding & ER Stress ⓘ

CHOP↑, 5,   cl‑CHOP↑, 1,   p‑eIF2α↑, 1,   ER Stress↓, 1,   ER Stress↑, 7,   GRP78/BiP↓, 1,   GRP78/BiP↑, 2,   HSP27↓, 1,   HSP27↑, 1,   HSP90↓, 3,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 3,   Beclin-1↑, 1,   LC3B-II↑, 2,   LC3II↑, 2,   LC3s↑, 1,   TumAuto↑, 5,  

DNA Damage & Repair ⓘ

ATM↑, 1,   BRCA1↑, 1,   CHK1↑, 1,   DFF45↑, 1,   DNAdam↓, 1,   DNAdam↑, 7,   DNArepair↓, 1,   DNMT1↓, 1,   DNMTs↓, 2,   p16↑, 1,   P53↑, 16,   PARP↑, 1,   cl‑PARP↑, 14,   PCNA↓, 6,   SIRT6↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 9,   CDK2↑, 1,   p‑CDK2↓, 1,   CDK4↓, 6,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 17,   cycE/CCNE↓, 4,   P21?, 1,   P21↑, 12,   RB1↓, 1,   p‑RB1↓, 3,   TumCCA?, 1,   TumCCA↑, 18,  

Proliferation, Differentiation & Cell State ⓘ

ALDH1A1↓, 2,   CD133↓, 5,   CD44↓, 6,   CDK8↓, 1,   cFos↓, 2,   CIP2A↓, 2,   cMET↓, 2,   CSCs↓, 11,   EMT↓, 16,   ERK↓, 7,   ERK↑, 1,   p‑ERK↓, 1,   p‑ERK↑, 1,   FOXO↑, 1,   p‑FOXO3↓, 1,   Gli↓, 1,   Gli1↓, 1,   GSK‐3β↓, 2,   GSK‐3β↑, 2,   p‑GSK‐3β↓, 2,   HDAC↓, 5,   HDAC1↓, 2,   HDAC3↓, 1,   HDAC8↓, 1,   HH↓, 1,   IGFBP3↑, 1,   mTOR↓, 8,   p‑mTOR↓, 1,   mTORC1↓, 2,   mTORC2↓, 1,   Nanog↓, 6,   Nanog↑, 1,   Nestin↓, 1,   NOTCH↓, 3,   NOTCH1↓, 3,   NOTCH3↓, 1,   OCT4↓, 6,   OCT4↑, 1,   p300↓, 1,   PI3K↓, 10,   PTCH1↓, 1,   PTCH2↓, 1,   PTEN↑, 4,   PTPN6↑, 1,   RAS↓, 4,   Shh↓, 2,   SHP1↑, 1,   Smo↓, 1,   SOX2↓, 2,   STAT1↓, 1,   STAT3↓, 16,   p‑STAT3↓, 3,   STAT6↓, 1,   TAZ↓, 1,   TCF↓, 2,   TOP2↓, 1,   TumCG↓, 7,   Wnt↓, 5,   Wnt/(β-catenin)↓, 2,  

Migration ⓘ

5LO↓, 1,   AEG1↓, 1,   AntiAg↑, 1,   AP-1↓, 2,   Ca+2↑, 3,   Ca+2↝, 2,   CD31↓, 1,   COL1↓, 1,   COL3A1↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 7,   EM↑, 1,   FAK↓, 3,   p‑FAK↓, 1,   GLI2↓, 1,   ITGB1↓, 1,   ITGB6↓, 1,   Ki-67↓, 4,   LEF1↓, 3,   MMP13↓, 1,   MMP2↓, 13,   MMP7↓, 3,   MMP9↓, 14,   MMPs↓, 5,   N-cadherin↓, 3,   PDGF↓, 1,   PKCδ↓, 4,   RAGE↓, 1,   Rho↓, 1,   Slug↓, 10,   Smad1↓, 1,   SMAD3↓, 1,   SMAD4↑, 1,   Snail↓, 13,   SOX4↓, 1,   SOX4↑, 2,   TET1↓, 1,   TGF-β↓, 2,   TGF-β↑, 1,   TIMP1↑, 3,   TIMP2↑, 4,   TSP-1↑, 1,   TumCA↓, 1,   TumCI↓, 11,   TumCMig↓, 7,   TumCP↓, 13,   TumMeta↓, 8,   Twist↓, 6,   uPA↓, 4,   VCAM-1↓, 1,   Vim↓, 6,   Zeb1↓, 3,   β-catenin/ZEB1↓, 9,   β-catenin/ZEB1↑, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 14,   ATF4↑, 1,   ATF4↝, 1,   EGFR↓, 8,   Endoglin↑, 1,   Hif1a↓, 7,   VEGF↓, 19,   VEGFR2↓, 5,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT1↓, 1,   NHE1↓, 1,   P-gp↓, 6,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX2↓, 11,   CXCR4↓, 2,   ICAM-1↓, 1,   IFN-γ↓, 2,   IKKα↓, 3,   IL6↓, 3,   IL8↓, 2,   Inflam↓, 4,   JAK↓, 1,   JAK1↓, 3,   JAK2↓, 2,   NF-kB↓, 17,   NF-kB↑, 1,   p‑NF-kB↑, 1,   p65↓, 2,   PD-1↓, 1,   PD-L1↓, 1,   PGE2↓, 2,   TNF-α↓, 3,  

Cellular Microenvironment ⓘ

IM↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 6,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↑, 5,   BioAv↝, 1,   BioEnh↑, 1,   ChemoSen↓, 1,   ChemoSen↑, 14,   CYP1A2↑, 1,   CYP2A3/CYP2A6↓, 1,   Dose↓, 1,   Dose↝, 5,   Dose∅, 1,   eff↓, 6,   eff↑, 12,   Half-Life↓, 2,   Half-Life↝, 2,   MDR1↓, 2,   MRP1↓, 1,   P450↓, 2,   RadioS↑, 7,   selectivity↑, 10,  

Clinical Biomarkers ⓘ

AR↓, 2,   BRCA1↑, 1,   EGFR↓, 8,   HER2/EBBR2↓, 2,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 3,   Ki-67↓, 4,   LDH↓, 1,   Myc↓, 2,   PD-L1↓, 1,   RAGE↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 6,   AntiTum↑, 2,   cardioP↑, 1,   chemoP↑, 2,   ChemoSideEff↓, 1,   hepatoP↑, 1,   neuroP↑, 1,   OS↑, 1,   RenoP↑, 1,   Risk↓, 1,   toxicity↓, 1,   TumVol↓, 2,   TumW↓, 2,  
Total Targets: 379

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 5,   GPx1↑, 1,   GSH↑, 2,   lipid-P↓, 2,   MDA↓, 1,   NRF2↑, 2,   ROS↓, 6,   SOD1↑, 1,   SOD2↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↓, 1,   IronCh↑, 1,  

Core Metabolism/Glycolysis ⓘ

FASN↓, 1,  

Cell Death ⓘ

MAPK↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Proliferation, Differentiation & Cell State ⓘ

STAT3↓, 1,  

Migration ⓘ

AntiAg↑, 1,   AP-1↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1↓, 1,   IL10↑, 1,   IL12↓, 1,   IL1β↓, 2,   IL4↓, 1,   IL5↓, 1,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 3,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 4,   Dose↝, 2,   eff↓, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 2,   NOS2↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   radioP↑, 1,   toxicity↓, 2,   toxicity↝, 1,  
Total Targets: 44

Scientific Paper Hit Count for: survivin, BIRC5
19 Thymoquinone
8 Resveratrol
7 EGCG (Epigallocatechin Gallate)
7 Quercetin
6 Silymarin (Milk Thistle) silibinin
5 Curcumin
4 Artemisinin
4 Ashwagandha(Withaferin A)
4 Baicalein
4 Boswellia (frankincense)
4 Sulforaphane (mainly Broccoli)
4 Fisetin
4 Honokiol
4 Piperlongumine
3 Apigenin (mainly Parsley)
3 Berbamine
3 Berberine
3 Betulinic acid
3 Deguelin
3 Gambogic Acid
3 Garcinol
2 5-fluorouracil
2 Silver-NanoParticles
2 Alpha-Lipoic-Acid
2 Cisplatin
2 Docetaxel
2 Capsaicin
2 Ellagic acid
2 Luteolin
2 Lycopene
2 Magnetic Fields
2 Naringin
2 Phenethyl isothiocyanate
2 Rosmarinic acid
2 salinomycin
2 Aflavin-3,3′-digallate
1 Coenzyme Q10
1 Andrographis
1 Gemcitabine (Gemzar)
1 immunotherapy
1 chitosan
1 Bufalin/Huachansu
1 brusatol
1 Bruteridin(bergamot juice)
1 Chrysin
1 Cinnamon
1 Citric Acid
1 Dichloroacetate
1 Genistein (soy isoflavone)
1 Butyrate
1 Emodin
1 Fucoidan
1 doxorubicin
1 Magnolol
1 HydroxyTyrosol
1 Chemotherapy
1 Mushroom Shiitake, AHCC
1 Oleuropein
1 Phenylbutyrate
1 Piperine
1 isoflavones
1 Shikonin
1 Selenite (Sodium)
1 Ursolic acid
1 Urolithin
1 Zerumbone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:299  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page